

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

HE 20.4210.982/SUPP.7

**CUMULATIVE
SUPPLEMENT 7**

AUG '82 - MAR '83

REFERENCE
DOES NOT CIRCULATE

PHARMACY
RM 308
• A653
3rd ed.
Suppl. 7

THE UNIVERSITY
OF MICHIGAN

MAY 25 1983


UNIVERSITY
LIBRARY

SERIAL

The University
of Michigan
Pharmacy
Library

**APPROVED
PRESCRIPTION
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
3RD EDITION**



UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 10 1983

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month and the past two quarters.

- C. APPLICANT (NAME) CHANGES Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
NATCON CHEMICAL CO INC	NATCON CORPORATION	NATCON
ENDO LABORATORIES INC SUB	DUPONT PHARMACEUTICALS/	
EI DUPONT DE NEMOURS AND	EI DU PONT DE NEMOURS	
CO INC	AND CO INC	DUPONT PHARMS/DUPONT
WESTERN RESEARCH	PHARMACEUTICAL BASICS	
LABORATORIES INC	INC	PHARM BASICS

The reader should consult this special list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 3rd Edition, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

D. THERAPEUTIC EQUIVALENCE EVALUATIONS EXAMPLES Chelsea Laboratories has performed an acceptable bioavailable/bioequivalence study for its 500mg sulfasalazine tablets. The therapeutic equivalence evaluation was changed, therefore, from BP to AB. On page 2-11 of the 3rd Edition of this publication, Chelsea's sulfasalazine tablet was used as an example of a therapeutically inequivalent product. The designation of the therapeutic equivalence code in the example for the 4th Edition, scheduled for publication in October, 1983, will be replaced.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the List composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

<u>CATEGORIES COUNTED</u>	<u>JULY '82 (BASELINE)</u>	<u>OCT '82</u>	<u>JAN '83</u>
DRUG PRODUCTS LISTED	6303	6401	6488
SINGLE SOURCE	1885 (30%)	1899 (29.7%)	1910 (29.4%)
MULTISOURCE(1)	4418 (70%)	4502 (70.3%)	4578 (70.5%)
THERAPEUTICALLY EQUIVALENT	3456 (54.8%)	3533 (55.2%)	3610 (55.6%)
NOT THERAPEUTICALLY EQUIVALENT	954 (15.1%)	960 (15.0%)	959 (14.8%)
EXCEPTIONS(2)	8 (0.1%)	9 (0.1%)	9 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	8	18
NUMBER OF APPLICANTS	303	302	308

B. ACTIVITY FOR SUPPLEMENT NUMBER 7 AND CUMULATIVE SINCE JANUARY '83

	<u>FEB '83</u>	<u>MAR '83</u>	<u>CUMULATIVE</u>
DRUG PRODUCTS ADDED:			
NEWLY APPROVED	33	59	92
DESI EFFECTIVE	33	54	87
REMARKETED	0	0	0
DRUG PRODUCTS REMOVED:			
WITHDRAWN APPROVAL	0	5	5
RX TO OTC SWITCH	6	15	21
DISCONTINUED MARKETING	0	0	0
NET GAIN IN DRUG PRODUCTS	0	1	1
SINGLE SOURCE PRODUCTS APPROVED	6	14	20
MULTISOURCE DRUG PRODUCTS APPROVED	27	44	71
NEW MOLECULAR ENTITIES APPROVED:	8	12	20
AS THE ENTITY	25	42	67
AS A SALT, ESTER OR DERIVATIVE	3	0	3
OF THE ENTITY	2	0	2
	1	0	1

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS

DRUG PRODUCT LIST

CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '82 - MARCH '83

> DLT > /ACETAMINOPHEN/ASPIRIN/COCAINE PHOSPHATE/ (PAGE 3-1)

> DLT > /CAPSULE/ ORAL/
 > DLT > /CODEINE/ASPIRIN/APAP FORMULA NO. 2/
 > DLT > /FIRST TEXAS SCHERER/ 150MG/60MG/15MG/
 > DLT > /CODEINE/ASPIRIN/APAP FORMULA NO. 3/
 > DLT > /FIRST TEXAS SCHERER/ 150MG/60MG/30MG/
 > DLT > /CODEINE/ASPIRIN/APAP FORMULA NO. 4/
 > DLT > /FIRST TEXAS SCHERER/ 150MG/60MG/60MG/

ACETAMINOPHEN/ CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA GENERIC PHARMS/IVY 300MG/30MG

AA ACETAMINOPHEN W/ CODEINE PHOSPHATE
 /AA/ /CARBRICK/SA CARBRICK/ 325MG/30MG/

ACETAMINOPHEN/ HYDROCODONE BITARTRATE (PAGE 3-2)

CAPSULE; ORAL

BANGAP HQ

> ADD > AA ONEAL JONES&FELDMAN 500MG/5MG

> ADD > AA LORCET-HD

> ADD > AA DM GRAHAM LABS 500MG/5MG

TABLET; ORAL

DURADYNE DHC

> ADD > AA ONEAL JONES&FELDMAN 500MG/5MG

ACETAMINOPHEN/ PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

TALACEN

STERLING DRUG 650MG/EQ 25MG BASEM

ACETAZOLAMIDE (PAGE 3-3)

TABLET; ORAL

ACETAZOLAMIDE

AB ASCOT HOSP PHARMS 250MG

ACYCLOVIR SODIUM (PAGE 3-4)

INJECTABLE; INJECTION

ZOVIRAX

BURROUGHS WELLCOME EQ 500MG BASE/VIALM

ALBUTEROL SULFATE (PAGE 3-4)

SYRUP; ORAL

PROVENTIL

EQ 2MG BASE/5MLM

ALCLOMETASONE DIPROPIONATE (PAGE 3-5)

CREAM; TOPICAL

VADERM

0.05%M

OINTMENT; TOPICAL

VADERM

0.05%M

/ALUMINUM CHLORHYDROXY ALLANTOINATE/ PRENTHISOLONE/ (PAGE 3-5)

/CREAM/ TOPICAL/

/NETT-DERM/

/0.25%0.5%1/

/ALUMINUM NICOTINATE/ (PAGE 3-5)

/TABLET/ ORAL/

/NICALEX/

/MERRELL DOWN CHEM/ 625MG/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION

HEPATAMINE 8%

AM MCGAW/AM HOSP 87M

NOVAMINE 8.5%

CUTTER LABORATORIES 8.5%M

NOVAMINE 11.4%

CUTTER LABORATORIES 11.4%M

RENAMIN M/O ELECTROLYTES

TRAVENOL LABS

6.5%M

AMINOACETIC ACID (PAGE 3-7)

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

/AT/ /AM MCGAW/AM HOSP/ 1.5GM/100ML/

GLYCINE 1.5% IN PLASTIC CONTAINER

AT AM MCGAW/AM HOSP 1.5GM/100ML

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
(PAGE 3-38)

TABLET, CONTROLLED RELEASE; ORAL

TAVIST D

DORSEY LABS/SANDOZ EQ 1MG BASE; 75MGX

CROMOLYN SODIUM (PAGE 3-42)

SOLUTION; NASAL

NASALCROM

FISONS

42M

CYCLOPENTOLATE HYDROCHLORIDE (PAGE 3-44)

SOLUTION/DROPS; OPHTHALMIC

PENTOLAIR

PHARMAFAIR

12M

AT

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION

CYTOXAN

HEAD JOHNSON/B-M

1GM/VIALX

2GM/VIALX

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

SYRUP; ORAL

CYPROHEPTADINE HCL

BAY LABORATORIES

2MG/5MLX

AA

TABLET; ORAL

CYPROHEPTADINE HCL

ASCOT HOSP PHARMS

/PREMO PHARM LABS/

LEMON

MD PHARMACEUTICAL

4MGX

/2MG/

4MG

4MGX

AA

AA

AA

DANTROLENE SODIUM (PAGE 3-45)

CAPSULE; ORAL

DANTRIUM

NORNICH-EATON/MORTON/75MG/

> DLT >

/SUSPENSION; ORAL/

/DANTRIUM/

/NORNICH-EATON/MORTON/25MG/5ML/

> DLT >

> DLT >

> DLT >

DEXAMETHASONE (PAGE 3-47)

TABLET; ORAL

DEXAMETHASONE

/BP/ /LEDERLE LABS/AM CYAN/0.25MG/

/BP/ /1.5MG/

/BP/ /ROXANE LABORATORIES 2MGX

/BP/ /WEST-WARD/ /0.75MG/

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

INJECTABLE; INJECTION

DEXAMETHASONE

AP ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML

AP EQ 10MG PHOSPHATE/MLX

/AP/ DEXAMETHASONE SODIUM PHOSPHATE

/ELKINS-SINN/AHROBINS/ EQ 4MG PHOSPHATE/ML/

OINTMENT; OPHTHALMIC

DECAIDRON

AT MS&D/MERCK EQ 0.05% PHOSPHATE

AT DEXAIR EQ 0.05% PHOSPHATEX

AT PHARMAFAIR

SOLUTION/DROPS; OPHTHALMIC

DEXAMETHASONE SODIUM PHOSPHATE

/AT/ BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

/AT/ /MAURRY BIOLOGICAL/ /EQ 0.1% PHOSPHATE/

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECAIDRON

AT MS&D MERCK EQ 0.1% PHOSPHATE

AT DEXAMETHASONE SODIUM PHOSPHATE

AT MAURRY BIOLOGICAL EQ 0.1% PHOSPHATE

DEXEDRONEPHENETAMINE MALEATE; PSEUDOEPHEDRINE SULFATE (PAGE 3-49)

TABLET; ORAL

/BP/ /SOPHROL/

/BP/ /SCHERING/

/2MG/50MG/

TABLET; CONTROLLED RELEASE; ORAL

/BP/ /SOPHROL/

/BP/ /SCHERING/

/2MG/50MG/

DEXTRAMPHETAMINE SULFATE (PAGE 3-49)

TABLET; ORAL

DEXTRAMPHETAMINE SULFATE

/AA/ /STANLABS/SIMPAN/ /5MG/

DEXTROSE (PAGE 3-50)

INJECTABLE; INJECTION

DEXTROSE 60%

AP AM MCGAW/AM HOSP 60GM/100MLM

DEXTROSE: POTASSIUM CHLORIDE (PAGE 3-52)

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC

CONTAINER

AP AM MCGAW/AM HOSP 5GM/100ML:75MG/100MLM

AP TRAVENOL LABS 5GM/100ML:75MG/100ML

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC

CONTAINER

AP AM MCGAW/AM HOSP 5GM/100ML:150MG/100MLM

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC

CONTAINER

AP AM MCGAW/AM HOSP 5GM/100ML:220MG/100MLM

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC

CONTAINER

AP TRAVENOL 5GM/100ML:224MG/100ML

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC

CONTAINER

AP AM MCGAW/AM HOSP 5GM/100ML:300MG/100MLM

DIATRIZOATE MEGLUMINE (PAGE 3-54)

INJECTABLE; INJECTION

ANGIOVIST 282

AP BERLEX/SCHERING AG 60%^M

AP UROVIST MEGLUMINE DIU/GT 30%^M

AP BERLEX/SCHERING AG 30%^M

SOLUTION; URETHRAL

UROVIST CYSTO

AT BERLEX/SCHERING AG 30%^M

AT UROVIST CYSTO PEDIATRIC 30%^M

AT BERLEX/SCHERING AG 30%^M

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION

ANGIOVIST 292

AP BERLEX/SCHERING AG 52%:82%^M

AP ANGIOVIST 370

AP BERLEX/SCHERING AG 66%:10%^M

SOLUTION; ORAL, RECTAL

GASTROVIST

AA BERLEX/SCHERING AG 66%:10%^M

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION

UROVIST SODIUM 300

AP BERLEX/SCHERING AG 50%^M

DICLOXACILLIN SODIUM (PAGE 3-55)

CAPSULE; ORAL

PAIRCECIL

>_ADD> AB MYETH LABS/AMMO

EQ 500MG BASEM

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-56)

CAPSULE; ORAL

TENUCAP

MERRELL DOW/DOW CHEM 25MGM

DIETHYLSTILBESTROL (PAGE 3-56)

TABLET; ORAL

DIETHYLSTILBESTROL

/BP/ /NEST-NARD/ /1MG/

DILTIAZEM HYDROCHLORIDE (PAGE 3-57)

TABLET; ORAL

CARDIZEM

MARION LABORATORIES EQ 30MG BASEM

EQ 60MG BASEM

DIMENHYDRINATE (PAGE 3-57)

INJECTABLE; INJECTION

DIMENHYDRINATE

/AP/ /CENTRAL PHARMS/ /50MG/ML/

/SUPPOSITIONS: RECTAL/

/PRAMAXINE/

/SEARLE PHARMS/ /100MG/

DINOPROST TROMETHAMINE (PAGE 3-58)

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

UPJOHN

/5MG/ML/

EQ 5MG BASE/ML

ERGOTAMINE TARTRATE (PAGE 3-64)

TABLET; SUBLINGUAL

AA ERGOMAR 2MG $\times$
FISONS
AA WIGRETTES 2MG $\times$
ORGANON/AKZONA

ERYTHROMYCIN (PAGE 3-64)

ointment; OPHTHALMIC

ILOTYCIN 5MG/GM
DISTA PRODS/LILLY

SOLUTION; TOPICAL

AT A/T/S 22 $\times$
HOECHST-ROUSSEL
> ADD >
T-STAI 22 $\times$
> ADD >
WESTWOOD PHARMS

TABLET, ENTERIC COATED; ORAL

ILOTYCIN
AB /BX/ 1250MG/
DISTA PRODS/LILLY
AB /BX/ 250MG/
DISTA PRODS/LILLY

ERYTHROMYCIN ESTOLATE (PAGE 3-64)

SUSPENSION; ORAL

AB ERYTHROMYCIN ESTOLATE
NATL PHARM MFG/BARRE EQ 125MG BASE/5ML $\times$
AB EQ 250MG BASE/5ML $\times$

AB ILOSONE
DISTA PRODS/LILLY EQ 125MG BASE/5ML
AB EQ 250MG BASE/5ML

ESTROGENS, ESTERIFIED (PAGE 3-67)

TABLET; ORAL

AB /BX/ 0.025MG/
GLYCESTRIN/
AB /BX/ 0.025MG/
FARST, TEXAS/SCHERER/
AB /BX/ 0.025MG/
FARST, TEXAS/SCHERER/

ESTRONE (PAGE 3-68)

INJECTABLE; INJECTION

BP NATURAL ESTROGENIC SUBSTANCE-ESTRONE 2MG/ML $\times$
CARTER-GLOGAU LABS

/ETHINYL ESTRADIOL; ETHINODIOL DIACETATE; FERROUS FUMARATE/
(PAGE 3-69)

/TABLET; ORAL-28/
/FEMINEX-28/
/SEARLE/SEARLE PHARMS/0.05MG; 1MG; 75MG/

ETONIDATE (PAGE 3-71)

INJECTABLE; INJECTION

AP AMIDATE 2MG/ML $\times$
ABBOTT LABORATORIES
AP HYPOHIDATE 2MG/ML $\times$
JANSSEN PHARMA

FENFLURAMINE HYDROCHLORIDE (PAGE 3-71)

TABLET, CONTROLLED RELEASE; ORAL

PONDIMIN 60MG $\times$
AH ROBINS

FLUCINOLONE ACETONIDE (PAGE 3-72)

CREAM; TOPICAL

AT FLUCINOLONE ACETONIDE 0.012 $\times$
E FOUGERA/BYK-GULDEN 0.0252 $\times$
AT 0.012 $\times$
AT PHARMADERM/BYK-GULDEN 0.012 $\times$
AT 0.0252 $\times$
> ADD >
> ADD >
AT FLUOTREX 0.0252 $\times$
SAVAGE LABS/BYK-GLDN 0.0252 $\times$

ointment; TOPICAL

AT FLUCINOLONE ACETONIDE 0.0252 $\times$
E FOUGERA/BYK-GULDEN 0.0252 $\times$
AT 0.0252 $\times$
AT PHARMADERM/BYK-GULDEN 0.0252 $\times$
> ADD >
> ADD >
AT FLUOTREX 0.0252 $\times$
SAVAGE LABS/BYK-GLDN 0.0252 $\times$

SOLUTION; TOPICAL

AT FLUCINOLONE ACETONIDE 0.012 $\times$
E FOUGERA/BYK-GULDEN 0.012 $\times$
AT 0.012 $\times$
AT PHARMADERM/BYK-GULDEN 0.012 $\times$
AT FLUCITD
> ADD >
> ADD >
AT HERBERT LABS/ALLERGN 0.012 $\times$
> ADD >
> ADD >
AT FLUOTREX 0.012 $\times$
SAVAGE LABS/BYK-GLDN 0.012 $\times$

FLUOROURACIL (PAGE 3-73)

INJECTABLE; INJECTION
FLUOROURACIL
 AP CARTER-GLOSAU LABS 50MG/ML
 AP HARCHAR LABORATORIES 50MG/ML

FOLIC ACID (PAGE 3-74)

TABLET; ORAL
FOLIC ACID
 > ADD > AA UNIT DOSE LABS 1MG

FUROSEMIDE (PAGE 3-75)

TABLET; ORAL
FUROSEMIDE
 AB PARKE-DAVIS/M-L 20MG
 AB 40MG
 AB SUPERPHARM 40MG

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION
GENTAMICIN SULFATE
 PHARM SPEC ASSOC
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER
 EQ 40MG BASE/ML
 EQ 0.8MG BASE/ML
 EQ 80MG BASE/100ML
 > ADD > AP TRAVENOL LABS

GONADORELIN HYDROCHLORIDE (PAGE 3-77)

INJECTABLE; INJECTION
 FACTREL
 AYERST LABS/AMHO
 EQ 0.1MG BASE/VIAL
 EQ 0.5MG BASE/VIAL

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-77)

SOLUTION/DROPS; OPHTHALMIC
NEOHYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
 PHARMAFAIR
 AT 0.025MG/ML; EQ 1.75MG BASE/ML;
 AT 5,000 UNITS/ML
 0.025MG/ML; EQ 1.75MG BASE/ML;
 10,000 UNITS/ML

GUANABENZ ACETATE (PAGE 3-78)

TABLET; ORAL
 MYTENSIN
 MYETH LABS/AMHO
 EQ 4MG BASE
 EQ 8MG BASE

GUANADREL SULFATE (PAGE 3-78)

TABLET; ORAL
 HYLOREL
 UPJOHN
 10MG
 25MG

HALOPERIDOL (PAGE 3-78)

/CONCENTRATE; ORAL/
 /HALDOL/
 /MCNEIL LABORATORIES//2MG/ML/
 /INJECTABLE; INJECTION/
 /HALDOL/
 /MCNEIL LABORATORIES//5MG/ML/

HALOPERIDOL LACTATE (PAGE 3-79)

CONCENTRATE; ORAL
 HALDOL
 MCNEIL LABORATORIES EQ 2MG BASE/ML
 INJECTABLE; INJECTION
 HALDOL
 MCNEIL LABORATORIES EQ 5MG BASE/ML

HEPARIN CALCIUM (PAGE 3-79)

INJECTABLE; INJECTION
 CALCIPARINE
 /CHOPAY LABORATORIES/ /25,000 UNITS/ML/
 AM CRITICAL CARE/ANS 25,000 UNITS/ML

HEPARIN SODIUM (PAGE 3-79)

INJECTABLE; INJECTION
 HEPARIN SODIUM
 /INOLEX/
 /AP/ 1,000 UNITS/ML/
 /AP/ 5,000 UNITS/ML/
 /AP/ 10,000 UNITS/ML/
 SODIUM HEPARIN
 /CORP. LABORATORIES/
 /AP/ 1,000 UNITS/ML/
 /AP/ 5,000 UNITS/ML/
 /AP/ 10,000 UNITS/ML/
 /AP/ 20,000 UNITS/ML/
 /AP/ 20,000 UNITS/ML/

HISTAMINE PHOSPHATE (PAGE 3-82)

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE
ELI LILLY

0.15MG/ML/
0.5MG/ML/
0.5MG/ML/
EQ 0.1MG BASE/ML
EQ 0.2MG BASE/ML
EQ 1MG BASE/ML
EQ 1MG/ML/
EQ 0.36MG BASE/ML

VITARINE/NEST CHEM

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE (PAGE 3-82)

SYRUP; ORAL
BAYCOTAN

BAY LABORATORIES 1.5MG/5ML; 5MG/5ML

HYCODAN

DUPONT PHARMS/DUPONT 1.5MG/5ML; 5MG/5ML

> ADD >
> ADD > AA
> ADD > AA

HYALURONIDASE (PAGE 3-82)

INJECTABLE; INJECTION
/ALTRASE/
/AP/ /SEARLE PHARMS/

150 UNITS/VIAL/
MYDASE
/AP/ /MYETH LABS/AMHO/
150 UNITS/VIAL/
150 UNITS/VIAL

HYDRALAZINE HYDROCHLORIDE (PAGE 3-82)

TABLET; ORAL

HYDRALAZINE HCL

PAR PHARMACEUTICALS 10MG
/AA/ /PREMO PHARM LABS/ 25MG/
/AA/ /5MG/
/AA/ 50MG
AA LEMMON

HYDROCHLOROTHIAZIDE (PAGE 3-83)

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AD/ ROXANE LABORATORIES 25MG/
/AB/ ROXANE LABORATORIES 25MG

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-85)

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/ PARKE-DAVIS/N-L 25MG; 25MG

HYDROCORTISONE (PAGE 3-85)

LOTION; TOPICAL

BALNEOL-HQ

AT ROWELL LABORATORIES 1/2M

MYTONE

AT DERMIK/ROBER-ANCHEN 1/2

AT 2.52M

NUTRACORT

/AT/ /OWEN LABS/ALCON LABS/ 0.52/

/AT/ /1/2/

AT OWEN LABS/DERM PRODS 0.52

AT 1/2

AT 2.52M

OINTMENT; TOPICAL

HYNAC

AT NMC LABS 1/2M

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-88)

SOLUTION; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

AT PHARMFAIR 1/2; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

SUSPENSION; OTIC

OTICAIR

AT PHARMFAIR 1/2; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

HYDROCORTISONE ACETATE (PAGE 3-88)

AEROSOL; TOPICAL

EPIFOAM

/AT/ REED & CARNICK 1/2

/AT/ /HYDROCORTISONE/ 1/2/

/AT/ /BLOCK DRUG/

AEROSOL; RECTAL

CORTIFOAM

REED & CARNICK 10%

HYDROCORTISONE BUTYRATE (PAGE 3-89)

CREAM; TOPICAL

LOCOID

AT GIST-BROCADES/NETH 0.12

AT OWEN LABS/DERM PRODS 0.12M

OINTMENT; TOPICAL

LOCOID

GIST-BROCADES/NETH 0.12M

ISOPROTERENOL HYDROCHLORIDE (PAGE 3-97)

INJECTABLE; INJECTION
148/ / 148EN3/
148/ / VITATINE WEST. CHEM/ / 0.2MG/ML/
ISOPROTERENOL HCL
AP INVENEX LABS/DEXTER 0.2MG/ML

SOLUTION; INHALATION
ISOPROTERENOL HCL
ARMOUR PHARM

0.0312M
 0.0622M

ISOTRETINOIN (PAGE 3-98)

CAPSULE; ORAL
ACCUTANE
HOFFMANN-LA ROCHE / 5MG/
20MGX

> DLT >
 > ADD >

LEUCOVORIN CALCIUM (PAGE 3-98)

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
LEDERLE LABS/AM CYAN/ / 5MG/ML/
50MG/VIAL/
EQ 5MG BASE/ML
EQ 50MG BASE/VIAL

WELLCOVORIN
BURROUGHS WELLCOME EQ 5MG BASE/MLX

LIDOCAINE (PAGE 3-99)

OINTMENT; TOPICAL
LIDOCAINE
147/ / CREBB/ / 52/

LIDOCAINE HYDROCHLORIDE (PAGE 3-100)

INJECTABLE; INJECTION
LIDOCAINE HCL
AP ABBOTT LABORATORIES 102M

SOLUTION; ORAL
BAYLOCAINE
AT BAY LABORATORIES 22M

SOLUTION; TOPICAL
BAYLOCAINE
AT BAY LABORATORIES 42M

LOPERAMIDE HYDROCHLORIDE (PAGE 3-102)

CAPSULE; ORAL
INODIUM
> DLT >/46/
> DLT >/46/
JANSSEN PHARMA 2MG
/ORTHO. PHARMACEUTICAL/ 2113/

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE (PAGE 3-103)

INJECTABLE; INJECTION

PLASMA-LYTE A IN PLASTIC CONTAINER
AP TRAVENOL LABS 30MG/100ML; 37MG/100ML; 368MG/100ML;
AP 526MG/100ML; 502MG/100MLX

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER
/ABBOTT. LABORATORIES/ / 14MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML/
ABBOTT LABORATORIES 30MG/100ML; 37MG/100ML; 222MG/100ML;
526MG/100ML; 502MG/100ML

MALATHION (PAGE 3-104)

LOTION; TOPICAL
PRIODERM
PURDUE FREDERICK 0.52M

MAPROTYLINE HYDROCHLORIDE (PAGE 3-104)

TABLET; ORAL
LUDIONIL
CIBA/CIBA-GEIGY 75MGX

MEPIVACAIN HYDROCHLORIDE (PAGE 3-107)

INJECTABLE; INJECTION
CARBOCaine
AP BREON LABS/STERLING 12
MEPIVACAIN HCL
AP INTL MEDICATION SYS 12M

MEPROBAMATE (PAGE 3-107)

TABLET; ORAL
MEPROBAMATE
/46/ / LEDERLE LABS/AM. CYAN/ 200MG/

METHADONE HYDROCHLORIDE (PAGE 3-110)

SOLUTION; ORAL
METHADONE HCL

ROXANE LABORATORIES 10MG/5MLM

TABLET; ORAL

DOLOPHINE HCL

ELI LILLY

5MG

10MG

> ADD > AA

> ADD > AA

METHADONE HCL

ROXANE LABORATORIES

5MG

10MG

> ADD > AA

> ADD > AA

METHANTHLENE BROMIDE (PAGE 3-111)

INJECTABLE; INJECTION

BARTHELEME

SEARLE/SEARLE PHARMS/50MG/MLM

METHOCARBAMOL (PAGE 3-112)

TABLET; ORAL

METHOCARBAMOL

ASCOT HOSP PHARMS

500MG

750MG

1000MG

> DLT > AA

> ADD > AA

GENERIC PHARM/IVY

BOOTS LABORATORIES

750MG

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL

AGUATENSEN

WALLACE LABS/C-W

WALLACE LABS/C-W

METHYCLOTHIAZIDE

MYLAN PHARMS

2.5MG

5MG

METHYLPREDNISOLONE ACETATE (PAGE 3-115)

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

MAURRY BIOLOGICAL 40MG/MLM

80MG/MLM

BP

BP

METHYLPREDNISOLONE SODIUM SUCCINATE (PAGE 3-115)

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

INTL MEDICATION SYS

EQ 40MG BASE/VIALM

EQ 125MG BASE/VIALM

EQ 500MG BASE/VIALM

EQ 1GM BASE/VIALM

AP

AP

AP

AP

METHYLTESTOSTERONE (PAGE 3-115)

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER DRUG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

10MG

TABLET; ORAL

METHYLTESTOSTERONE

LANNETT

10MG

25MG

BP

BP

METOCLOPRAMIDE HYDROCHLORIDE (PAGE 3-116)

SYRUP; ORAL

REGAN

AH ROBINS

EQ 5MG BASE/5MLM

> ADD >

> ADD >

> ADD >

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION

METRO I.V.

AM MCGAW/AM HOSP

500MG/100MLM

AP

TABLET; ORAL

METRONIDAZOLE

BARR LABORATORIES

250MG

500MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

250MG

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

TABLET; ORAL

MINOCIN

LEDERLE LABS/AM CYAN EQ 50MG BASEX
EQ 100MG BASEX

OINTMENT; TOPICAL

MYSTATIN

AT BYK-GULDEN 100,000 UNITS/GM

MYSTATIN (PAGE 3-123)MYSTADINOLIN (PAGE 3-118)
PLICAMYCIN

TABLET; ORAL

MYSTATIN

AA CHELSEA LABORATORIES 500,000 UNITSX

OXOLINTIC ACID (PAGE 3-125)NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE (PAGE 3-119)

TABLET; ORAL

TALWIN NX

WINTHROP LABS/STERL 0.5MG;EQ 50MG BASEX

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-121)

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MS&D/MERCK

EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

NETILMICIN SULFATE (PAGE 3-121)

INJECTABLE; INJECTION

NETROMYCIN

SCHERING

EQ 10MG BASE/MLX

EQ 25MG BASE/MLX

EQ 100MG BASE/MLX

NIACIN (PAGE 3-121)

TABLET; ORAL

NIACIN

/AA/ /GENERIC PHARM/IVY/ /500MG/

NITROGLYCERIN (PAGE 3-122)

INJECTABLE; INJECTION

NITROL

AP KREMERS-URBAN

0.8MG/MLX

NITROSTAT

AP PARKE-DAVIS/M-L

0.8MG/ML

PENICILLIN G PROCAINE (PAGE 3-129)

INJECTABLE; INJECTION

PFIZERPEN-AS

/PFIZER LABS/PFIZER/ /1,200,000 UNITS/ML/

> DLT >

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL

OXYTETRACYCLINE HCL

/AB/ /LEDERLE LABS/AM CYAN/EQ 250MG BASE/

PENICILLIN G POTASSIUM (PAGE 3-128)

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

ELI LILLY

200,000 UNITS/VIAL

500,000 UNITS/VIAL

1,000,000 UNITS/VIAL

5,000,000 UNITS/VIAL

500,000 UNITS/VIAL

JOHN D COPANOS

TABLET; ORAL

PENICILLIN G POTASSIUM

/JOHN D. COPANOS/

/100,000 UNITS/

/200,000 UNITS/

/250,000 UNITS/

/400,000 UNITS/

/500,000 UNITS/

PENTOBARBITAL SODIUM (PAGE 3-131)

CAPSULE; ORAL
PENTOBARBITAL SODIUM
 /AA/ /LENNON/ /100MG/

PHENYLBUTAZONE (PAGE 3-134)

CAPSULE; ORAL
PHENYLBUTAZONE
 AB CHELSEA LABORATORIES 100MG

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
 /AA/ /CORD LABORATORIES/ /35MG/
 /AA/ /REID-PROVIDENT LABS/ /35MG/
 SPRX-3
 AA REID-PROVIDENT LABS 35MG
 AA X-TROZINE
 AA REXAR PHARMACAL 35MG

CAPSULE, CONTROLLED RELEASE; ORAL
 MELFIAT-105
 BC REID-PROVIDENT LABS 105MG
 SPRX-105
 BC REID-PROVIDENT LABS 105MG
 X-TROZINE L.A.
 BC REXAR PHARMACAL 105MG

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
 /AA/ /GENERIC PHARMACY/ /35MG/

PHENTERMINE HYDROCHLORIDE (PAGE 3-133)

CAPSULE; ORAL
 /ADIPEX-8/
 /LENNON/
 PHENTERMINE HCL
 AA LANNETT 30MG

TABLET; ORAL
 /ADIPEX/
 /LENNON/
 /ADIPEX-8/
 /LENNON/
 ADIPEX-P
 AA LENTON 37.5MG
 PHENTERMINE HCL
 AA CAMALL 37.5MG
 /AA/ /CORD LABORATORIES/ /8MG/
 TORA
 AA REID-PROVIDENT LABS 8MG

PINDOLOL (PAGE 3-135)

TABLET; ORAL
 VISKEN
 SANDOZ PHARMS/SANDOZ 5MG
 10MG
 15MG

POLYMYXIN B SULFATE (PAGE 3-136)

INJECTABLE; INJECTION
 AEROSPORIN
 > ADD > AP BURROUGHS WELLCOME 500,000 UNITS/VIAL
 > ADD > POLYMYXIN B SULFATE
 > ADD > AP PFIZER LABS/PFIZER 500,000 UNITS/VIAL

POTASSIUM CHLORIDE (PAGE 3-137)

CAPSULE, CONTROLLED RELEASE; ORAL
 TIMKAP
 /BC/ /BERLEX/SCHERING/ /8MEQ/
 BC CIBA/CIBA-GEIGY 8MEQ

POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-138)

INJECTABLE; INJECTION
 SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.075% IN PLASTIC
 AP AM MCGAW/AM HOSP 75MG/100ML; 900MG/100ML
 AP TRAVENOL LABS 75MG/100ML; 900MG/100ML
 SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.15% IN PLASTIC
 AP AM MCGAW/AM HOSP 150MG/100ML; 900MG/100ML
 AP TRAVENOL LABS 150MG/100ML; 900MG/100ML
 SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.22% IN PLASTIC
 AP AM MCGAW/AM HOSP 220MG/100ML; 900MG/100ML
 AP SODIUM CHLORIDE 0.9% & POTASSIUM CHLORIDE 0.22% IN PLASTIC
 AP TRAVENOL LABS 220MG/100ML; 900MG/100ML
 SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.5% IN PLASTIC
 AP AM MCGAW/AM HOSP 300MG/100ML; 900MG/100ML
 AP TRAVENOL LABS 300MG/100ML; 900MG/100ML
 SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 10MEQ (K) IN PLASTIC
 AP TRAVENOL LABS 150MG/100ML; 900MG/100ML
 SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 AP TRAVENOL LABS 150MG/100ML; 900MG/100ML
 AP TRAVENOL LABS 300MG/100ML; 900MG/100ML

POTASSIUM CHLORIDE; SODIUM CHLORIDE (PAGE 3-138)

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 40MEQ (K) IN

PLASTIC

AP TRAVENOL LABS 300MG/100ML; 900MG/100MLX

TABLET; ORAL

PROBENECID
/AB/ BECKMAN LABS/BECKMAN/500MG/PROBENECID (PAGE 3-142)PROCAINAMIDE HYDROCHLORIDE (PAGE 3-143)POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE (PAGE 3-138)

INJECTABLE; INJECTION

THAM-E

ABBOTT LABORATORIES /0.37MG/ML; 1.75MG/ML; 16MG/ML/
370MG/VIAL; 1.75GH/VIAL; 36GH/VIAL

CAPSULE; ORAL

PROCAINAMIDE HCL

ASCOT HOSP PHARMS

375MGX> ADD > ABPROCHLORPERAZINE EDISYLATE (PAGE 3-144)PRAZICQUANTEL (PAGE 3-139)

TABLET; ORAL

BILTRICIDE

MILES PHARMS/MILES 600MGXPREDNISOLONE (PAGE 3-139)

CREAM; TOPICAL

METI-DERM

SCHERING 0.5%

TABLET; ORAL

PREDNISOLONE

/BX/ PARÉPAC/KALIPHARMA/ 15MG/BX UNIT DOSE LABS 5MGXPREDNISOLONE ACETATE; SULFACETAMIDE SODIUM (PAGE 3-140)

SUSPENSION/DROPS; OPHTHALMIC

METIRYD

SCHERING

0.5%; 1.0%AI

SULPHREN

AI MURO PHARMACEUTICAL 0.5%; 1.0%PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-140)

SOLUTION/DROPS; OPHTHALMIC

PREDAIR FORTE

PHARMAFAIR

EQ 0.9% PHOSPHATEXPREDNISONE (PAGE 3-141)

TABLET; ORAL

PREDNISONE

UNIT DOSE LABS

5MGX10MGX20MGX

BX

BX

BX

PROPARACATINE HYDROCHLORIDE (PAGE 3-146)

SOLUTION/DROPS; OPHTHALMIC

PARACATINEAI PRO PHARMA/STERI-MED 0.5%PROMETHAZINE HYDROCHLORIDE (PAGE 3-145)

INJECTABLE; INJECTION

/BP/ PHENDEN-50//AB/ CENTRAL PHARMS/50MG/ML/

SYRUP; ORAL

BAYMETHAZINEAA BAY LABORATORIES 5.25MG/5MLXBAYMETHAZINE FORTISAA BAY LABORATORIES 25MG/5MLX

TABLET; ORAL

PROMETHAZINE HCL/BP/ LEPERLE LABS/AN CYAN/25MG//BP/ 50MG/PROPANTHELINE BROMIDE (PAGE 3-146)

TABLET; ORAL

PROPANTHELINE BROMIDE

ASCOT HOSP PHARMS

AA 15MGX/AA/ LEPERLE LABS/AN CYAN/15MG/

SODIUM CHLORIDE (PAGE 3-155)INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT LABORATORIES 9MG/MLM

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT LABORATORIES 2MG/MLM

AP

SODIUM POLYSTYRENE SULFONATE (PAGE 3-158)SUSPENSION; ORAL, RECTAL

SPS

CAROLINA MED PRODS 15GM/60MLM

SOYBEAN OIL (PAGE 3-159)INJECTABLE; INJECTION

INTRALIPID 20%

CUTLER-VITRUM 20%

AP

TRAVAMULSION 20%

TRAVENOL LABS 20%

AP

SPIRONOLACTONE (PAGE 3-159)TABLET; ORAL

SPIRONOLACTONE

ASCOT HOSP PHARMS 25MGM

PARKE-DAVIS/N-L 25MGM

AB

SUCCINYLCHOLINE CHLORIDE (PAGE 3-159)INJECTABLE; INJECTION

SUCCOSTRIN

ER SQUIBB AND SONS 50MG/ML

/AB/

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)CREAM; VAGINAL

SULNAC

NYC LABORATORIES 3.7Z; 2.86Z; 3.42Z; 0.64ZM

TRIPLE SULFA

CLAY-PARK LABS 3.7Z; 2.86Z; 3.42Z; 0.64ZM

AT

SULFACETAMIDE SODIUM (PAGE 3-160)ointment; OPHTHALMIC

SULFAIR 10

PHARMAFAIR 10%

AT

SULFACETAMIDE SODIUM (PAGE 3-160)SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

PHARMAFAIR 10ZM

SULTEN-10

MURO PHARMACEUTICAL 10ZM

AT

/SULFAMETER/ (PAGE 3-161)/TABLET; ORAL/

/SULFA/

/BERLEX/SCHERING/ 500MG/

SULFAMETHOXAZOLE (PAGE 3-161)TABLET; ORAL

SULFAMETHOXAZOLE

ASCOT HOSP PHARMS 500MGM

AB

SULFAMETHOXAZOLE; TRIMETHOPRIM (PAGE 3-161)SUSPENSION; ORAL

SMZ-TMP

BIOCRAFT LABS 200MG/5ML; 40MG/5MLM

SULFATRIM

NATL PHARM MFG/BARRE 200MG/5ML; 40MG/5MLM

SULFATRIM PEDIATRIC

NATL PHARM MFG/BARRE 200MG/5ML; 40MG/5MLM

AB

SULFASALAZINE (PAGE 3-162)TABLET; ORAL

SULFASALAZINE

/BP/ /CHELSEA LABORATORIES/500MG/

AB CHELSEA LABORATORIES 500MG

AB

SULFINPYRAZONE (PAGE 3-162)CAPSULE; ORAL

ANTURANE

CIBA/CIBA-GEIGY 200MG

SULFINPYRAZONE

BARR LABORATORIES 200MGM

ZENITH LABORATORIES 200MGM

AB

TABLET; ORAL

SULFINPYRAZONE

BARR LABORATORIES 100MGM

AB

SULFISOXAZOLE (PAGE 3-162)

TABLET; ORAL

SULFISOXAZOLE

/BP/ /FRENCO PHARM LABS/ /500MG/ 500MG

SYRUP; ORAL

AGUAPHYLLIN

AA /SLO-PHYLLIN-80/ 80MG/15ML
/AA/ /POONER LABORATORIES/ 80MG/15ML
AA /SLO-PHYLLIN 80MG/15ML

> ADD > TECHNETIUM, TC-99M, ALBUMIN COLLOID KII (PAGE 3-164)

> ADD > INJECTABLE; INJECTION

MICROLITE

MED DIAG/NE NUCLEAR N/A

> ADD >

TECHNETIUM, TC-99M, MEDRONATE KII (PAGE 3-164)

INJECTABLE; INJECTION

AMERSCAN

AP AMERSHAM/RADIOCHEM N/A

TECHNETIUM, TC-99M, PENTETATE KII (PAGE 3-165)

INJECTABLE; INJECTION

/CANTICHEN/TECHNETIUM 99m TcPa/ DTPA

TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

INJECTABLE; INJECTION

TECHNETIUM TC 99M SULFUR COLLOID /SINGOR ANT/ /2MG/ML

TETRACYCLINE (PAGE 3-166)

SYRUP; ORAL

/ROSTET/

/AB/ /AM ROBIN/

ED 125MG HCL/5ML/

ED 125MG HCL/5ML/

THALLOUS CHLORIDE, TL-201 (PAGE 3-168)

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP AMERSHAM/RADIOCHEM 1MCI/ML

THEOPHYLLINE (PAGE 3-168)

SYRUP; ORAL

AGUAPHYLLIN

AA /SLO-PHYLLIN-80/ 80MG/15ML
/AA/ /POONER LABORATORIES/ 80MG/15ML
AA /SLO-PHYLLIN 80MG/15ML

TABLET; ORAL

SLO-PHYLLIN

/BP/ /POONER LABORATORIES/ 100MG/ 200MG
/BP/ /POONER LABORATORIES/ 100MG/ 200MG
BD WILLIAM H RORER 100MG
BD 200MG

TABLET, CONTROLLED RELEASE; ORAL

THEOCONTIN

PURDUE FREDERICK 400MG

THEOCHRON

BC FOREST LABORATORIES 300MG

THIAMINE HYDROCHLORIDE (PAGE 3-169)

INJECTABLE; INJECTION

THIAMINE HCL

AP MAURY BIOLOGICAL 100MG/ML

THIORIDAZINE HYDROCHLORIDE (PAGE 3-170)

TABLET; ORAL

MELLARIL

> ADD > AB SANDOZ PHARMS/SANDOZ 10MG
> ADD > AB 25MG
> ADD > AB 50MG

THIORIDAZINE HCL

MYLAN PHARMS

> ADD > AB 10MG
> ADD > AB 25MG
> ADD > AB 50MG

TOLBUTAMIDE (PAGE 3-171)

TABLET; ORAL

TOLBUTAMIDE

> ADD > AB ASCOT HOSP PHARMS 500MG

TRETINOIN (PAGE 3-172)

GEL; TOPICAL

RETIN-A

ORTHO PHARMACEUTICAL/0.05%

TRIAMCINOLONE ACETONIDE (PAGE 3-173)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
 PHARMAFAIR 0.025%
 0.1%
 0.5%
 > ADD > AT
 > ADD > AT
 > ADD > AT
 > ADD > AT
 > ADD > AT

LOTION; TOPICAL
KENALOG
 ER SQUIBB AND SONS 0.025%
 0.1%
TRIAMCINOLONE ACETONIDE
 NATL PHARM MFG/BARRE 0.025%
 0.1%
 0.1%

ONJMENT; TOPICAL
TRIAMCINOLONE ACETONIDE
 BYK-GULDEN 0.025%
 0.1%
 0.1%

TRIAZOLAM (PAGE 3-174)

TABLET; ORAL
 HALCION
 UPJOHN 0.25MG
 0.5MG

TRICHLORMETHIAZIDE (PAGE 3-174)

TABLET; ORAL
TRICHLORMETHIAZIDE
 /BP/ /FRENCH PHARM LABS/ 4MG/
 BP LEMMON 4MG

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

CONCENTRATE; ORAL
TRIFLUOPERAZINE
 TFP

TABLET; ORAL
TRIFLUOPERAZINE HCL
 ZENITH LABORATORIES
 EQ 1MG BASE 100
 EQ 2MG BASE 100
 EQ 5MG BASE 100
 EQ 10MG BASE 100

TRIMETHOBENZAMIDE HYDROCHLORIDE (PAGE 3-176)

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
 BEECHAM LABS/BEECHAM 100MG/ML
 100MG/ML
 100MG/ML

TRIMETHOPRIM (PAGE 3-176)

TABLET; ORAL
PROLOPRIM
 BURROUGHS WELLCOME 200MG
 200MG
 200MG
 HOFFMANN-LA ROCHE

TRIMIPRAMINE MALEATE (PAGE 3-176)

CAPSULE; ORAL
 SURMONTIL
 IVES LABS/AMHO EQ 100MG BASE

TRIPROLIDINE HYDROCHLORIDE (PAGE 3-177)

SYRUP; ORAL
 BAYIDYL
 BAY LABORATORIES 1.25MG/5ML
 1.25MG/5ML

TRIMETHAMINE (PAGE 3-177)

INJECTABLE; INJECTION
 THAM
 ABBOTT LABORATORIES 3.6MG/100ML
 3.6MG/100ML

TROPICAMIDE (PAGE 3-178)

SOLUTION/DROPS; OPHTHALMIC
HYDRIACYL
 ALCON LABORATORIES 1%
 1%
 1%
 PRO PHARMA/STERI-MED 12H

VITAMIN A (PAGE 3-179)

CAPSULE; ORAL
VITAMIN A
 /AA/ /LEDERLE LABS/AM CYAN 50,000 IU/
 50,000 IU/

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '82 - MARCH '83

VITAMIN A PALMITATE (PAGE 3-179)

CAPSULE; ORAL
/DERM-A-CAPS/
/AA/ /PHARMS ASSOC/EEACH /EQ 50,000 UNITS/BASE/
> DLT > /VITAMIN A/
> DLT > /AA/ /ROXANE LABORATORIES//EQ 50,000 UNITS/BASE/

XENON, XE-127 (PAGE 3-181)

GAS; INHALATION
XENON XE 127
MALLINCKRODT
5MCI/VIALM
10MCI/VIALM

/ZOMEPHAC SODIUM/ (PAGE 3-181)

/TABLET; ORAL/
/ZOMAX/
/MCNEIL LABORATORIES//EQ 100MG/BASE/

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL
ATHROMBIN
/BP/ /PURDUE, FREDERICK/ /5MG/
/BP/ /PURDUE, FREDERICK/ /10MG/
BX BX PURDUE FREDERICK 5MG
BX BX 10MG
COUMADIN
/BP/ /ENDO LABS/DUPONT/ /2MG/
/BP/ /ENDO LABS/DUPONT/ /2.5MG/
/BP/ /ENDO LABS/DUPONT/ /5MG/
/BP/ /ENDO LABS/DUPONT/ /7.5MG/
/BP/ /ENDO LABS/DUPONT/ /10MG/
BX BX 2MG
BX BX 2.5MG
BX BX 5MG
BX BX 7.5MG
BX BX 10MG
PANMARFIN
/BP/ /ABBOTT LABORATORIES//2MG/
/BP/ /ABBOTT LABORATORIES//2.5MG/
/BP/ /ABBOTT LABORATORIES//5MG/
/BP/ /ABBOTT LABORATORIES//7.5MG/
/BP/ /ABBOTT LABORATORIES//10MG/
BX BX 2MG
BX BX 2.5MG
BX BX 5MG
BX BX 7.5MG
BX BX 10MG
ABBOTT LABORATORIES
2MG
5MG
7.5MG
10MG
WARFARIN SODIUM
BOLAR PHARMACEUTICAL 2MGH
2.5MGH
5MGH
7.5MGH
10MGH
BX BX
BX BX
BX BX
BX BX
BX BX

WATER FOR INJECTION, STERILE (PAGE 3-180)

LIQUID; N/A
BACTERIOSTATIC WATER IN PLASTIC CONTAINER
ABBOTT LABORATORIES 100%N

ADDENDUM
DESI PENDING LIST
CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '82 - MARCH '83

CURRENT STATUS - INEFFECTIVE

/BETAADINE/ /PURDUE FREDERICK/
/POXYDINE-ADPINE/

DIPYRIDAMOLE /PREFO PHARM LABS/
LEHMAN

/NEOMYCIN SULFATE-HYDROCORTISONE/ /BYK-SULDEN/
/HYDROCORTISONE-NEOMYCIN SULFATE/

/PATHILON/ /LEDERLE LABS/AM CYAN/
/TRIDINE-ETHYL CHLORIDE/

/PATHILON W/ PHENOBARBITAL/ /LEDERLE LABS/AM CYAN/
/PHENOBARBITAL-TRIDINE-ETHYL CHLORIDE/

CURRENT STATUS - 'EXEMPT' (COURT ORDER)

/BETOCLAKE/ /MERRELL DON DON CHEN/
/BEX-PANTHENE-1, NIACINAMIDE, PYRIDOXINE, HYDROCHLORIDES/
/RIBOFLAVIN, THIAMINE, HYDROCHLORIDE/

BUTIBEL /MCNEIL LABORATORIES/
WALLACE LABS/C-N

DIPYRIDAMOLE ASCOT HOSP PHARMS
DIPYRIDAMOLE

DIPYRIDAMOLE HALSEY DRUG
DIPYRIDAMOLE

DIPYRIDAMOLE /PHARMADYNE LABS/
CHELSEA LABORATORIES

DIPYRIDAMOLE SUPERPHARM
DIPYRIDAMOLE

/FOLIESYN/ /LEDERLE LABS/AM CYAN/
/ASCORBIC ACID, FOLIC ACID, NIACINAMIDE,/
/PYRIDOXINE, HYDROCHLORIDE, RIBOFLAVIN, SODIUM PANTOTHENATE,/
/THIAMINE, HYDROCHLORIDE/

HYBEPHEN BEECHAM LABS/BEECHAM
ATROPINE SULFATE; HYOSCYAMINE SULFATE; PHENOBARBITAL;
SCOPOLAMINE HYDROBROMIDE

ISOSORBIDE DINITRATE INWOOD LABS/FOREST
ISOSORBIDE DINITRATE

ISOSORBIDE DINITRATE UNIT DOSE LABS
ISOSORBIDE DINITRATE

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

NANDROLONE DECANOATE LENNON
NANDROLONE DECANOATE

NITRO-TIME TIME-CAP LABS
NITROGLYCERIN

NITROBON INWOOD LABS/FOREST
NITROGLYCERIN

NITROGLYCERIN VITARINE/NEST CHEM
NITROGLYCERIN

NITROSTAT 22 PARKE-DAVIS/M-L
NITROGLYCERIN

PENTAERYTHRITOL TETRANITRATE INWOOD LABS/FOREST
PENTAERYTHRITOL TETRANITRATE

PENTRASPAN VITARINE/NEST CHEM
PENTAERYTHRITOL TETRANITRATE

TRANSERM-NITRO 10 /ALZA/
CIBA/CIBA-GEIGY

TRANSERM-NITRO 2.5 /ALZA/
CIBA/CIBA-GEIGY

TRANSERM-NITRO 5 /ALZA/
CIBA/CIBA-GEIGY

/VIT-SYNERAL/ /HISONS/
/ASCORBIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN,/
/THIAMINE, JOSEPHEROLS, VITAMIN A5, VITAMIN D/

UNIVERSITY OF MICHIGAN



3 9015 07293 2919